[
  {
    "ts": null,
    "headline": "Tracking Ray Dalio's Bridgewater Associates 13F Portfolio - Q2 2025 Update",
    "summary": "Tracking Ray Dalio's Bridgewater Associates 13F Portfolio - Q2 2025 Update",
    "url": "https://finnhub.io/api/news?id=58c187a768f5bc4c3434410510e342c2b411f0a5ea7e700bddd565110013faf7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755818681,
      "headline": "Tracking Ray Dalio's Bridgewater Associates 13F Portfolio - Q2 2025 Update",
      "id": 136473977,
      "image": "",
      "related": "CI",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=58c187a768f5bc4c3434410510e342c2b411f0a5ea7e700bddd565110013faf7"
    }
  },
  {
    "ts": null,
    "headline": "Elevance Health: Piggy Bank Or Headache?",
    "summary": "Elevance Health: Piggy Bank Or Headache?",
    "url": "https://finnhub.io/api/news?id=a2635aa72627e81346716898f8bf8e172798bc7332a40f83c1e7e413ca4f2817",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755798385,
      "headline": "Elevance Health: Piggy Bank Or Headache?",
      "id": 136471079,
      "image": "",
      "related": "CI",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=a2635aa72627e81346716898f8bf8e172798bc7332a40f83c1e7e413ca4f2817"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying.",
    "summary": "The injection, called Yeztugo, is highly effective, but its list price is $28, 218 a year in the U.S.",
    "url": "https://finnhub.io/api/news?id=be6a70a6aff1c7fca4c0c3fb825b8b94f57db0bf9674ca31f395fafb6eb7f470",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755792900,
      "headline": "Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying.",
      "id": 136471519,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CI",
      "source": "Yahoo",
      "summary": "The injection, called Yeztugo, is highly effective, but its list price is $28, 218 a year in the U.S.",
      "url": "https://finnhub.io/api/news?id=be6a70a6aff1c7fca4c0c3fb825b8b94f57db0bf9674ca31f395fafb6eb7f470"
    }
  },
  {
    "ts": null,
    "headline": "Update: Market Chatter: CVS Health Won't Cover Gilead's New HIV Prevention Drug Yet",
    "summary": "(Update to add Gilead's comment in the fourth paragraph) CVS Health (CVS) has decided not to incl",
    "url": "https://finnhub.io/api/news?id=4bc881779c3de61e9ec0223c99188902d719f2054e596f1329f340b0e310734c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755782468,
      "headline": "Update: Market Chatter: CVS Health Won't Cover Gilead's New HIV Prevention Drug Yet",
      "id": 136467654,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CI",
      "source": "Yahoo",
      "summary": "(Update to add Gilead's comment in the fourth paragraph) CVS Health (CVS) has decided not to incl",
      "url": "https://finnhub.io/api/news?id=4bc881779c3de61e9ec0223c99188902d719f2054e596f1329f340b0e310734c"
    }
  },
  {
    "ts": null,
    "headline": "Karat Launches Partner Talent Solution to Elevate Contractor Engineering Quality",
    "summary": "SEATTLE, August 21, 2025--Karat, the trusted standard for measuring technical talent, today announced the launch of the industry’s first-ever solution for elevating contractor engineering quality. Shaped by Karat’s experience working with some of the world’s biggest enterprises, including Citi, Citizens Bank, and Cigna, the new Partner Talent Solution creates a unified standard that elevates contractor talent, accelerates placements, and reduces delivery risk. With this launch, Karat expands its",
    "url": "https://finnhub.io/api/news?id=8307fed7271bf979f68c2be30b7ee6997c748952be08045edbbcb0e3a429eb99",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755781200,
      "headline": "Karat Launches Partner Talent Solution to Elevate Contractor Engineering Quality",
      "id": 136467970,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CI",
      "source": "Yahoo",
      "summary": "SEATTLE, August 21, 2025--Karat, the trusted standard for measuring technical talent, today announced the launch of the industry’s first-ever solution for elevating contractor engineering quality. Shaped by Karat’s experience working with some of the world’s biggest enterprises, including Citi, Citizens Bank, and Cigna, the new Partner Talent Solution creates a unified standard that elevates contractor talent, accelerates placements, and reduces delivery risk. With this launch, Karat expands its",
      "url": "https://finnhub.io/api/news?id=8307fed7271bf979f68c2be30b7ee6997c748952be08045edbbcb0e3a429eb99"
    }
  },
  {
    "ts": null,
    "headline": "Warren Buffett's Modest Stake a Boost for UnitedHealth, But Work Left to be Done",
    "summary": "Berkshire Hathaway's (BRK.A, BRK.B) recent disclosure that it bought $1.6 billion of UnitedHealth Gr",
    "url": "https://finnhub.io/api/news?id=0dde0e0c14733dd4fe1015d8866701fc4f558f2ddbaeaef8d431d5ed86aeaeec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755778152,
      "headline": "Warren Buffett's Modest Stake a Boost for UnitedHealth, But Work Left to be Done",
      "id": 136467453,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CI",
      "source": "Yahoo",
      "summary": "Berkshire Hathaway's (BRK.A, BRK.B) recent disclosure that it bought $1.6 billion of UnitedHealth Gr",
      "url": "https://finnhub.io/api/news?id=0dde0e0c14733dd4fe1015d8866701fc4f558f2ddbaeaef8d431d5ed86aeaeec"
    }
  },
  {
    "ts": null,
    "headline": "Market Chatter: CVS Health Won't Cover Gilead's New HIV Prevention Drug Yet",
    "summary": "CVS Health (CVS) has decided not to include Gilead Sciences' (GILD) new HIV prevention drug, Yeztugo",
    "url": "https://finnhub.io/api/news?id=e63848e550ef812bca0552da187fba5b54b7291fa7137f25c22ab856146c21e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755772465,
      "headline": "Market Chatter: CVS Health Won't Cover Gilead's New HIV Prevention Drug Yet",
      "id": 136467660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CI",
      "source": "Yahoo",
      "summary": "CVS Health (CVS) has decided not to include Gilead Sciences' (GILD) new HIV prevention drug, Yeztugo",
      "url": "https://finnhub.io/api/news?id=e63848e550ef812bca0552da187fba5b54b7291fa7137f25c22ab856146c21e4"
    }
  },
  {
    "ts": null,
    "headline": "Strong Fundamentals Make Cigna (CI) a Compelling Value Play, Says Guggenheim",
    "summary": "The Cigna Group (NYSE:CI) is one of the deep value stocks to buy according to analysts. Cigna’s shares are up about 4% year-to-date, lagging the broader market. Still, the company’s favourable product mix and lack of exposure to Medicaid and Medicare have helped it avoid steeper losses seen elsewhere in the sector. On August 4, a […]",
    "url": "https://finnhub.io/api/news?id=1a27f5ee1e7332d3b9bb18e2b5054c53345c4260e0337e5c836aa9e2c3c17ef3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755748396,
      "headline": "Strong Fundamentals Make Cigna (CI) a Compelling Value Play, Says Guggenheim",
      "id": 136450626,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CI",
      "source": "Yahoo",
      "summary": "The Cigna Group (NYSE:CI) is one of the deep value stocks to buy according to analysts. Cigna’s shares are up about 4% year-to-date, lagging the broader market. Still, the company’s favourable product mix and lack of exposure to Medicaid and Medicare have helped it avoid steeper losses seen elsewhere in the sector. On August 4, a […]",
      "url": "https://finnhub.io/api/news?id=1a27f5ee1e7332d3b9bb18e2b5054c53345c4260e0337e5c836aa9e2c3c17ef3"
    }
  }
]